A message from our CEO

Thank you for taking the time to learn about Bexa. We’re working hard to continuously advance the sophistication of Bexa and to establish its role in the early detection of breast cancer through continued use and traditional clinical validation studies.  Both are delivering excellent results. 

The Bexa Team, Advisors, and Board of Directors are squarely focused on the lack of both participation in and access to early detection options, a quiet but very real tragedy.  Globally 90% of women will have no technology-assisted early detection option: that’s 1.3 billion women with little chance to beat the most common women’s cancer. During Covid, even fewer women are getting any form of early detection, making a bad problem much worse.  

Bexa represents a ‘win,’ for everyone.  Women get an option that can be made easily accessible to them, and new protection against the most common women’s cancer.  Governments, insurance companies now have an option to reduce cancer care costs in populations otherwise most often diagnosed at late and expensive stages of cancer.  And physicians and healthcare providers get a new and valuable service to add to their current offerings. 

Complicated guidelines that reflect the limitations of other technologies disappear with Bexa.  In the absence of radiation, and accuracy even in dense breast tissue, Bexa is a true universal solution.  Given the low-cost of the Bexa solution, truly no woman should be left without an early detection option.  There’s no surgery, no drug, no therapy that makes up for the impact of a breast cancer being diagnosed late that could have been diagnosed early.

Late-stage breast cancers aren’t a “women’sproblem”; they are every society’s problem because the impact of late-stage cancers is far broader than just medical outcomes and cancer treatment costs. Families are destabilized, income lost, school performance is affected…as asurvivor told me early in our journey, “everything is affected, and a lot is lost.” 

We’re a team that’s focused upon the realities of the current state of early detection, and acting to change the situation.  When the majority of women have no realistic option, failure to act, and act aggressively, is not okay. 

Joe Peterson, MD
Chairman & CEO